Gemopatrilat

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525165

CAS#: 160135-92-2

Description: Gemopatrilat is a drug which acts as an vasopeptidase inhibitor.


Price and Availability

Size
Price

Size
Price

Size
Price

Gemopatrilat is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 525165
Name: Gemopatrilat
CAS#: 160135-92-2
Chemical Formula: C19H26N2O4S
Exact Mass: 378.16133
Molecular Weight: 378.49
Elemental Analysis: C, 60.29; H, 6.92; N, 7.40; O, 16.91; S, 8.47


Synonym: Gemopatrilat; BMS 189921; BMS-189921; BMS189921.

IUPAC/Chemical Name: (6S)-Hexahydro-6-((alphaS)-alpha-mercaptohydrocinnamamido)-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid

InChi Key: YRSVDSQRGBYVIY-GJZGRUSLSA-N

InChi Code: InChI=1S/C19H26N2O4S/c1-19(2)10-6-9-14(18(25)21(19)12-16(22)23)20-17(24)15(26)11-13-7-4-3-5-8-13/h3-5,7-8,14-15,26H,6,9-12H2,1-2H3,(H,20,24)(H,22,23)/t14-,15-/m0/s1

SMILES Code: CC1(C)CCC[C@H](NC(=O)[C@@H](S)Cc2ccccc2)C(=O)N1CC(=O)O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, Rinehart JK, Iyer RA. Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans. Drug Metab Dispos. 2006 Jun;34(6):961-70. Epub 2006 Mar 15. PubMed PMID: 16540589.

2: Singh J, Kronenthal DR, Schwinden M, Godfrey JD, Fox R, Vawter EJ, Zhang B, Kissick TP, Patel B, Mneimne O, Humora M, Papaioannou CG, Szymanski W, Wong MK, Chen CK, Heikes JE, DiMarco JD, Qiu J, Deshpande RP, Gougoutas JZ, Mueller RH. Efficient asymmetric synthesis of the vasopeptidase inhibitor BMS-189921. Org Lett. 2003 Aug 21;5(17):3155-8. PubMed PMID: 12917005.

3: Laverman GD, Van Goor H, Henning RH, De Jong PE, De Zeeuw D, Navis G. Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. Kidney Int. 2003 Jan;63(1):64-71. PubMed PMID: 12472769.

4: Sagnella GA. Vasopeptidase inhibitors. J Renin Angiotensin Aldosterone Syst. 2002 Jun;3(2):90-5. Review. PubMed PMID: 12228848.

5: Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM. In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat. J Hypertens. 2001 May;19(5):941-6. PubMed PMID: 11393678.